InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
0.00%
)
US TECH 100
19,681.60
(
0.02%
)
Dow Jones
39,753.75
(
0.00%
)
Brent Oil
85.39
(
0.32%
)
Bitcoin
57,270.73
(
-0.14%
)
Post# of 252581
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

tinkershaw

Send PM Follow Ignore
Followers 13
Posts 325
Boards Moderated 0
Alias Born 01/15/2008

tinkershaw

Re: BTH post# 116419

Monday, 03/14/2011 5:01:24 PM

Monday, March 14, 2011 5:01:24 PM

Post# of 252581

Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.



A simple question by analysts as to "what good reason" may have been a valuable contribution to doing their job.

Whenever I see a citation like this, you know it is a PR job and nothing more.

Tinker
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up